Practical efficacy of olmesartan versus azilsartan in patients with hypertension: a multicenter randomized-controlled trial (MUSCAT-4 study).

Published on Mar 24, 2017in Blood Pressure Monitoring1.092
· DOI :10.1097/MBP.0000000000000229
Yuki Kakio6
Estimated H-index: 6
(Okayama University),
Haruhito A. Uchida15
Estimated H-index: 15
+ 4 AuthorsJun Wada63
Estimated H-index: 63
Sources
Abstract
BackgroundOlmesartan and azilsartan, angiotensin II receptor blockers (ARBs), are expected to decrease blood pressure more than the other ARBs. We conducted randomized-controlled trials to compare the practical efficacy of olmesartan with azilsartan.MethodsEighty-four patients treated with the conve
📖 Papers frequently viewed together
5 Citations
1 Citations
References57
Newest
#1Dena Ettehad (The George Institute for Global Health)H-Index: 3
#2Connor A. Emdin (The George Institute for Global Health)H-Index: 32
Last. Kazem Rahimi (The George Institute for Global Health)H-Index: 59
view all 9 authors...
Summary Background The benefits of blood pressure lowering treatment for prevention of cardiovascular disease are well established. However, the extent to which these effects differ by baseline blood pressure, presence of comorbidities, or drug class is less clear. We therefore performed a systematic review and meta-analysis to clarify these differences. Method For this systematic review and meta-analysis, we searched MEDLINE for large-scale blood pressure lowering trials, published between Jan ...
1,210 CitationsSource
#1Masaki Hatanaka (Osaka University)H-Index: 5
#2Jun-Ya Kaimori (Osaka University)H-Index: 11
Last. Hiromi Rakugi (Osaka University)H-Index: 94
view all 10 authors...
A potent angiotensin II type-1 receptor blocker, azilsartan, has been reported to reduce blood pressure more effectively than candesartan. Interestingly, azilsartan can also restore the circadian rhythm of blood pressure. We hypothesized that azilsartan could also improve salt sensitivity; thus, we examined the effect of azilsartan on sodium handling in renal tubules. Subtotal nephrectomized C57BL/6 mice received azilsartan (1.0 mg/kg/day), candesartan (0.3 mg/kg/day), or vehicle via the oral ro...
11 CitationsSource
#1Jackson T. Wright (Case Western Reserve University)H-Index: 63
#2Jeff D. Williamson (Wake Forest University)H-Index: 80
Last. Walter T. Ambrosius (Wake Forest University)H-Index: 59
view all 18 authors...
BACKGROUND The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain. METHODS We randomly assigned 9361 persons with a systolic blood pressure of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a target of less than 140 mm Hg (standard treatment). The primary composite outcome was myocar...
3,044 CitationsSource
#1Masanori Abe (Nihon University)H-Index: 50
#2Osamu Oikawa (Nihon University)H-Index: 8
Last. Masayoshi Soma (Nihon University)H-Index: 41
view all 4 authors...
Introduction: Angiotensin-converting enzyme 2 (ACE2) is a member of the renin-angiotensin system that degrades angiotensin (Ang) II to the seven-amino acid peptide fragment Ang-(1-7). We evaluated the changes in urinary ACE2 levels in response to treatment with the angiotensin II type 1 receptor blocker olmesartan in diabetes patients with nephropathy. Materials and methods: This prospective, open-label, interventional study was conducted with 31 type 2 diabetes patients with nephropathy. After ...
20 CitationsSource
#1Akinobu Maeda (YCU: Yokohama City University)H-Index: 14
#2Kouichi Tamura (YCU: Yokohama City University)H-Index: 33
Last. Satoshi Umemura (YCU: Yokohama City University)H-Index: 66
view all 14 authors...
In the present study, we examined the therapeutic effects of olmesartan, an angiotensin II (Ang II) type 1 receptor (AT1R)-specific blocker, in genetically obese diabetic KKAy mice, a model of human metabolic disorders with visceral obesity, with a focus on an olmesartan effect on the adipose tissue. Olmesartan treatment (3 mg/kg per day) for 4 weeks significantly lowered systolic blood pressure but did not affect body weight during the study period in KKAy mice. However, there were three intere...
12 CitationsSource
#1Toshio Ogihara (Osaka University)H-Index: 116
#2Kenjiro Kikuchi (Asahikawa Medical College)H-Index: 38
Last. Hiromi Rakugi (Osaka University)H-Index: 94
view all 30 authors...
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)
1,232 CitationsSource
#1Md. Abdul Hye Khan (MCW: Medical College of Wisconsin)H-Index: 12
#2Jan Neckář (MCW: Medical College of Wisconsin)H-Index: 14
Last. John D. Imig (MCW: Medical College of Wisconsin)H-Index: 76
view all 5 authors...
Purpose Angiotensin II type 1 receptor blockers (ARBs) are widely used in treating hypertension. In the present study, we tested the hypothesis that a novel ARB, azilsartan medoxomil (AZL-M) will prevent renal and cardiovascular injury in the spontaneously hypertensive obese rat (SHROB), a model of cardiometabolic syndrome.
16 CitationsSource
#1Jieyun You (Fudan University)H-Index: 7
Last. Yunzeng ZouH-Index: 55
view all 8 authors...
BACKGROUND: Notch1 signaling controls the cardiac adaptation to stress. We therefore aimed to validate whether olmesartan, a widely used angiotensin II type 1 receptor blocker, ameliorates cardiac remodeling and dysfunction via delta-like ligand 4 (DLL4)/Notch1 pathway in mice with chronic pressure overload. METHODS: Cardiac pressure overload was produced by transverse aortic constriction (TAC). A total of 35 wide-type C57BL/6J mice were randomly divided into sham group, TAC group, TAC + olmesar...
22 CitationsSource
#1Shin-ichiro Miura (Fukuoka University)H-Index: 42
#2Atsutoshi Okabe (Takeda Pharmaceutical Company)H-Index: 4
Last. Keijiro Saku (Fukuoka University)H-Index: 56
view all 5 authors...
The angiotensin II type 1 (AT1) receptor blocker (ARB) candesartan strongly reduces blood pressure (BP) in patients with hypertension and has been shown to have cardioprotective effects. A new ARB, azilsartan, was recently approved and has been shown to provide a more potent 24-h sustained antihypertensive effect than candesartan. However, the molecular interactions of azilsartan with the AT1 receptor that could explain its strong BP-lowering activity are not yet clear. To address this issue, we...
40 CitationsSource
#1Tamio TeramotoH-Index: 23
#2Jun SasakiH-Index: 35
Last. Koutaro YokoteH-Index: 53
view all 18 authors...
373 CitationsSource
Cited By1
Newest
#1Di Zhao (HAUST: Henan University of Science and Technology)H-Index: 4
#2Hui Liu (Zhengzhou University)H-Index: 5
Last. Pingshuan Dong (HAUST: Henan University of Science and Technology)H-Index: 5
view all 3 authors...
Objective The comparison of antihypertensive effects between azilsartan and olmesartan in patients with essential hypertension has been investigated in several studies. The results were not consistent. We performed this meta-analysis determining the antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension.
4 CitationsSource